Old Web
English
Sign In
Acemap
>
authorDetail
>
Andrew Laman
Andrew Laman
University of Pittsburgh
Medicine
Neutropenia
Pathology
Cyclophosphamide
Fludarabine
3
Papers
172
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase I/II study of rilotumumab (R) and erlotinib (E) in previously treated patients (pts) with metastatic NSCLC.
2015
Journal of Clinical Oncology
Ahmad A. Tarhini
Imran Rafique
Phu Tran
William E. Gooding
Liza C. Villaruz
Timothy F. Burns
David M. Friedland
Grace R. Tarabay
Andrew Laman
Dhaval R. Mehta
M. Sulecki
D. Petro
Mark S. Georgiadis
Kevin Kane
Sajid M. Peracha
Kiran K. Rajasenan
Alexis Megaludis
Lijun Dai
Mark A. Socinski
Show All
Source
Cite
Save
Citations (0)
Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia
2009
Journal of Clinical Oncology
Kenneth A. Foon
Michael Boyiadzis
Stephanie R. Land
Stanley M. Marks
Anastasios Raptis
L. Pietragallo
D. Meisner
Andrew Laman
Mathew Sulecki
Allyson Butchko
P. M. Schaefer
Diana Lenzer
Ahmad A. Tarhini
Show All
Source
Cite
Save
Citations (171)
Final Results of Lower Dose Fludarabine (F) and Cyclophosphamide (C), and High Dose Rituximab (R), (FCR-Lite) for Patients with Untreated Chronic Lymphocytic Leukemia (CLL).
2007
Blood
Ahmad A. Tarhini
Stephanie R. Land
L. Pietragallo
Andrew Laman
M. Sulecki
Stanley M. Marks
D. Meisner
P. M. Schaefer
Kenneth A. Foon
Show All
Source
Cite
Save
Citations (1)
1